Terms: = Leukemia AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Treatment
251 results:
1. Self-Stimulated Photodynamic Nanoreactor in Combination with cxcr4 Antagonists for Antileukemia Therapy.
Zhang Y; Chen L; Fu T; Xu A; Li K; Hao K; Lyu J; Wang Z; Kong F
ACS Appl Mater Interfaces; 2024 May; 16(17):21610-21622. PubMed ID: 38647446
[TBL] [Abstract] [Full Text] [Related]
2. Thymic-Epithelial-Cell-Dependent Microenvironment Influences Proliferation and Apoptosis of Leukemic Cells.
Patel SK; Zhdanovskaya N; Sergio I; Cardinale A; Rosichini M; Varricchio C; Pace E; Capalbo C; Locatelli F; Macone A; Velardi E; Palermo R; Felli MP
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338689
[TBL] [Abstract] [Full Text] [Related]
3. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract] [Full Text] [Related]
4. C-X-C motif chemokine receptor 4 inhibition promotes the effect of plantamajoside in hepatocellular carcinoma.
Sun J; Liu W; Fu H; Li Y; Huang J; Wang Y; Zhu L
Arab J Gastroenterol; 2024 Feb; 25(1):28-36. PubMed ID: 38220479
[TBL] [Abstract] [Full Text] [Related]
5. Motixafortide: First Approval.
Hoy SM
Drugs; 2023 Nov; 83(17):1635-1643. PubMed ID: 37996648
[TBL] [Abstract] [Full Text] [Related]
6. Killing two birds with one stone: CRISPR/Cas9 CCR5 knockout hematopoietic stem cells transplantation to treat patients with HIV infection and hematological malignancies concurrently.
Au TY; Arudkumar J; Assavarittirong C; Benjamin S
Clin Exp Med; 2023 Dec; 23(8):4163-4175. PubMed ID: 37500934
[TBL] [Abstract] [Full Text] [Related]
7. Theranostics in Hematooncology.
Buck AK; Serfling SE; Kraus S; Samnick S; Dreher N; Higuchi T; Rasche L; Einsele H; Werner RA
J Nucl Med; 2023 Jul; 64(7):1009-1016. PubMed ID: 37290799
[TBL] [Abstract] [Full Text] [Related]
8. Targeting cxcr4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Liu S; Xie SM; Liu W; Gagea M; Hanker AB; Nguyen N; Singareeka Raghavendra A; Yang-Kolodji G; Chu F; Neelapu SS; Marchese A; Hanash S; Zimmermann J; Arteaga CL; Tripathy D
Breast Cancer Res; 2023 Jun; 25(1):62. PubMed ID: 37280713
[TBL] [Abstract] [Full Text] [Related]
9. CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.
Alsadhan A; Chen J; Gaglione EM; Underbayev C; Tuma PL; Tian X; Freeman LA; Baskar S; Nierman P; Soto S; Itsara A; Ahn IE; Sun C; Bibikova E; Hartmann TN; Mhibik M; Wiestner A
Clin Cancer Res; 2023 Sep; 29(18):3612-3621. PubMed ID: 37227160
[TBL] [Abstract] [Full Text] [Related]
10. Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
Castellani F; Visentin A; Schirinzi E; Salvalaggio A; Cacciavillani M; Candiotto C; Baratè C; Cellini A; Bertorelle R; Siciliano G; Trentin L; Briani C
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37137530
[TBL] [Abstract] [Full Text] [Related]
11. The Regulation of Neutrophil Migration in Patients with Sepsis: The Complexity of the Molecular Mechanisms and Their Modulation in Sepsis and the Heterogeneity of Sepsis Patients.
Bruserud Ø; Mosevoll KA; Bruserud Ø; Reikvam H; Wendelbo Ø
Cells; 2023 Mar; 12(7):. PubMed ID: 37048076
[TBL] [Abstract] [Full Text] [Related]
12. whim Syndrome-linked cxcr4 mutations drive osteoporosis.
Anginot A; Nguyen J; Abou Nader Z; Rondeau V; Bonaud A; Kalogeraki M; Boutin A; Lemos JP; Bisio V; Koenen J; Hanna Doumit Sakr L; Picart A; Coudert A; Provot S; Dulphy N; Aurrand-Lions M; Mancini SJC; Lazennec G; McDermott DH; Guidez F; Blin-Wakkach C; Murphy PM; Cohen-Solal M; Espéli M; Rouleau M; Balabanian K
Nat Commun; 2023 Apr; 14(1):2058. PubMed ID: 37045841
[TBL] [Abstract] [Full Text] [Related]
13. IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia.
Fiordi B; Salvestrini V; Gugliotta G; Castagnetti F; Curti A; Speiser DE; Marcenaro E; Jandus C; Trabanelli S
Haematologica; 2023 Sep; 108(9):2396-2409. PubMed ID: 37021528
[TBL] [Abstract] [Full Text] [Related]
14. The Bone Marrow Immune Microenvironment in CML: treatment Responses, treatment-Free Remission, and Therapeutic Vulnerabilities.
Patterson SD; Copland M
Curr Hematol Malig Rep; 2023 Apr; 18(2):19-32. PubMed ID: 36780103
[TBL] [Abstract] [Full Text] [Related]
15. Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma.
Leipold AM; Werner RA; Düll J; Jung P; John M; Stanojkovska E; Zhou X; Hornburger H; Ruckdeschel A; Dietrich O; Imdahl F; Krammer T; Knop S; Rosenwald A; Buck A; Sander LE; Einsele H; Kortüm KM; Saliba AE; Rasche L
Leukemia; 2023 Mar; 37(3):650-658. PubMed ID: 36720972
[TBL] [Abstract] [Full Text] [Related]
16. The Monocytic Cell Line THP-1 as a Validated and Robust Surrogate Model for Human Dendritic Cells.
Hölken JM; Teusch N
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674966
[TBL] [Abstract] [Full Text] [Related]
17. Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling.
Anderson NR; Sheth V; Li H; Harris MW; Qiu S; Crossman DK; Kumar H; Agarwal P; Nagasawa T; Paterson AJ; Welner RS; Bhatia R
Leukemia; 2023 Mar; 37(3):560-570. PubMed ID: 36550214
[TBL] [Abstract] [Full Text] [Related]
18. cxcr4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance.
Jonart LM; Ostergaard J; Brooks A; Fitzpatrick G; Chen L; Gordon PM
Br J Haematol; 2023 May; 201(3):459-469. PubMed ID: 36535585
[TBL] [Abstract] [Full Text] [Related]
19. Managing Waldenström's macroglobulinemia with BTK inhibitors.
Buske C; Jurczak W; Salem JE; Dimopoulos MA
Leukemia; 2023 Jan; 37(1):35-46. PubMed ID: 36402930
[TBL] [Abstract] [Full Text] [Related]
20. Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.
Wang L; Tang J; Feng J; Huang Y; Cheng Y; Xu H; Miao Y
Front Immunol; 2022; 13():1001482. PubMed ID: 36325357
[TBL] [Abstract] [Full Text] [Related]
[Next]
